Printer Friendly

Morgan Stanley: Salesforce Shares Aren't Pricing In Strong Free Cash Flow Growth.

Byline: Dave Royse, inc. (NYSE:CRM) is being overlooked by investors despite strong revenue and free cash flow growth potential, according to Morgan Stanley.

The Analyst

Keith Weiss maintained an Overweight rating on Salesforce with a $178 price target.

The Thesis

A strong case for 25%-plus free cash flow growth isn't priced into Salesfore shares and that, coupled with investor concern around a slowdown in the core business, creates a "strong buying opportunity" in a core service-as-a-software asset, Weiss said in a Friday note. (See his track record here.)

The analyst said he sees a clear path for Salesforce to more than double revenues by fiscal 2023, even with merger and acquisition dilution in the near-term.

Salesforce shares have underperformed, advancing just 3% year-to-date against its software peer group thanks to M&A dilution, Weiss said.

The company earlier this summer sealed up a $15.7-billion acquisition of data analytics firm Tableau Software.

Salesforce enjoys a favorable competitive position, and there's healthy customer demand across its product offerings, the analyst said.

"With enterprise IT spend focused on digital transformation, Salesforce remains one of the best secularly positioned names in software and a long-term share gainer within an estimated $200B+ Total Addressable Market."

Price Action

Salesforce shares were down 1.84% at $140.73 at the close Monday.

Related Links:

KeyBanc: Salesforce Poised To Benefit From Data Opportunity After Tableau Acquisition

Tableau CEO On Synergies With Salesforce: The 'Best Of Both Worlds'

Photo courtesy of Salesforce.

Latest Ratings for CRM






Jun 2019



Mar 2019

Initiates Coverage On


Mar 2019

Initiates Coverage On


View More Analyst Ratings for CRM

View the Latest Analyst Ratings

(c) 2019 Benzinga does not provide investment advice. All rights reserved.

COPYRIGHT 2019 Accretive Capital LLC dba
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Date:Aug 12, 2019
Previous Article:Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts.
Next Article:Earnings Scheduled For August 13, 2019.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters